News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
45 Results
Type
Article (4)
Press Release (41)
Section
Business (4)
Deals (1)
Drug Development (13)
FDA (3)
Job Trends (1)
News (23)
Policy (5)
Tag
Alliances (4)
Approvals (3)
Best Places to Work (1)
Clinical research (10)
Events (1)
FDA (3)
Government (1)
Mergers & acquisitions (1)
Phase II (3)
Phase III (7)
Postmarket research (2)
Preclinical (1)
Regulatory (5)
Date
Last 365 days (3)
2024 (3)
2022 (2)
2021 (3)
2020 (8)
2019 (3)
2018 (1)
2017 (1)
2016 (3)
2014 (2)
2013 (1)
2012 (3)
2011 (5)
2010 (4)
Location
Asia (19)
Australia (33)
Europe (14)
45 Results for "clinuvel".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® and the future of photomedicine.
March 28, 2024
·
2 min read
Drug Development
Afamelanotide in fair-skinned Parkinson’s patients
CLINUVEL announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
June 17, 2024
·
6 min read
CLINUVEL Expands Pharmaceutical Portfolio
CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone.
November 7, 2021
·
4 min read
CLINUVEL expands DNA Repair Program
CLINUVEL has expanded its clinical program to evaluate the DNA reparative potential of afamelanotide in skin cells which have been damaged by ultraviolet (UV) and sun exposure.
March 23, 2021
·
5 min read
CLINUVEL Opens VALLAURIX R&D Centre In SingaporeBespoke Research & Development Centre to advance innovative pharmaceutical and OTC products
The CLINUVEL Group announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd.
August 31, 2020
·
7 min read
PRÉNUMBRA® - CLINUVEL’s Second Afamelanotide FormulationDrug to be evaluated in patients with acute and systemic diseases
CLINUVEL PHARMACEUTICALS revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development.
July 13, 2020
·
7 min read
CLINUVEL progresses innovative DNA Repair ProgramDrug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk
CLINUVEL PHARMACEUTICALS LTD announced the progression of its drug SCENESSE® to treat the disease xeroderma pigmentosum.
September 10, 2020
·
7 min read
CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients with acute stroke.
October 27, 2020
·
5 min read
FDA
FDA Approves Clinuvel’s Scenesse for Extreme Light Sensitivity
Scenesse is an under-the-skin implant. The drug is the company’s only approved product.
October 9, 2019
·
2 min read
·
Mark Terry
Press Releases
Vitiligo Market Size to Reach USD 439.1 Million by 2034, Impelled by Innovations in Phototherapy
August 5, 2024
·
12 min read
1 of 5
Next
